Research progress in targeted therapy for gastric cancer

Abstract

Gastric cancer is a common malignant tumor worldwide, and its incidence rate and mortality have always been in the forefront. Most gastric cancer patients in China are diagnosed in the middle or late stages, with an unsatisfactory 5- year survival rate and poor prognosis. Prior to the emergence of targeted therapy, the combination chemotherapy of fluorouracil and platinum based drugs was considered a first- line treatment option, but the clinical benefits were limited. Targeted therapy, as a current research hotspot and new treatment method in the field of cancer treatment, has been proven by practice, clinical trials, and basic research to significantly improve the survival rate of gastric cancer patients, especially those in the middle and late stages. This article introduces the latest research progress in targeted therapy for gastric cancer, including human epidermal growth factor receptor- 2 (HER2), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), etc., aiming to provide new ideas and directions for targeted therapy for gastric cancer.

Keywords

• gastric cancer; targeted therapy; human epidermal growth factor receptor- 2; epidermal growth factor receptor; fibroblast growth factor receptor